Most Read

The global trial called EV-301 compared PADCEV to chemotherapy in nearly 600 patients who had prior treatment with platinum-based chemotherapy and a PD-1/L1 inhibitor. Co-developed by the two

The vaccine candidate is being developed using Sanofi’s recombinant protein-based technology and GSK’s advanced adjuvant technology. Sanofi’s protein-based technology is currently used to produce an influenza vaccine. Both

The pharma major plans to advance the PCSK9 inhibitor programme into clinical development for dyslipidaemia and familial hypercholesterolemia in 2021. Dyslipidaemia is a condition in which there is

As part of the partnership, RDIF will supply 100 million doses of the vaccine to Dr. Reddy’s, after securing regulatory approval in India. Developed by the Gamaleya National

Magrolimab is an investigational monoclonal antibody, which has been developed to act against CD47 and macrophage checkpoint inhibitor. It is being developed in various hematologic and solid tumour

Situated at the company’s R&D headquarters in Boston, the new facility offers end-to-end research and development services to advance the development of next-generation cell therapies. The new R&D

HFB30132A is said to have been discovered, engineered, and developed in less than six months by the US-based HiFiBiO Therapeutics. The company said that its partnership with ABL

As per the terms of the deal, Gilead Sciences has offered to acquired 100% of Immunomedics for $88 per share in cash. Through the acquisition, Gilead Sciences gets

Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from